Dejun Wang

Introduction

Dejun Wang is a 62-year-old physician from Walnut, California, who was charged by federal indictment for the prohibited sale of prescription drug samples — allegedly selling sample drugs including Rybelsus, Ozempic, and Mounjaro to the owners of pharmacies in the San Gabriel Valley, who repackaged and dispensed them to customers. The charge was announced October 22, 2026, as part of a Los Angeles health care fraud takedown in which 15 defendants, including six medical professionals, were charged in schemes that collectively submitted $2 billion in fraudulent health care claims — what federal prosecutors called one of the largest takedowns in California’s recent history .

Background Information

Drug samples occupy a specific lane in pharmaceutical law: they are prescription drugs that are not intended to be sold, and are instead meant to promote the sale of the drug — given to physicians free of charge to hand to appropriate patients. The indictment against Wang, as announced by the U.S. Attorney’s Office for the Central District of California, alleges he turned that promotional pipeline into a resale business, selling samples of the diabetes and weight-loss drugs Rybelsus, Ozempic, and Mounjaro to pharmacy owners in the San Gabriel Valley who repackaged the samples and dispensed them to their own customers .

The Controversy or Incident That Led to Their Cancellation

Indicted, not convicted. Wang faces the accusations of a federal indictment; the Justice Department notes an indictment contains only allegations, and he is presumed innocent unless and until proven guilty beyond a reasonable doubt.

Wang’s case was one of the smaller-dollar indictments inside an enormous announcement day. The October 22 takedown grouped 15 defendants across schemes including a $1.6 billion sober-living fraud pipeline run by Nathan Young and his father David Young, $134 million in medically unnecessary arterial procedures, and $138 million in fraudulent Medicare hospice billing — with eight defendants arrested that Thursday and seven others expected to make initial appearances in Los Angeles, Texas, and Illinois. Wang’s indictment, charging the prohibited sale of prescription drug samples, stood apart as the takedown’s drug-diversion case rather than a billing fraud .

Federal officials cast the collective cases as a data-driven enforcement message. Assistant Attorney General Colin M. McDonald of the Justice Department’s National Fraud Enforcement Division said: “Our message is simple: if you steal health care dollars from the American taxpayer or abuse your position to harm patients, we are coming for you — and the data will lead us to you.” Bill Essayli, the first assistant U.S. attorney in California, said it was “especially egregious when doctors and other health care professionals, who pledged to do no harm, resort to petty greed and criminality” .

Public Reaction and Consequences

The takedown drew wide coverage for its scale — $2 billion in alleged fraudulent claims and one of California’s largest single-day health care fraud announcements — with Wang named among the six medical professionals charged. The FBI and HHS-OIG are investigating his case, and Assistant United States Attorney Sebastian Bellm of the General Crimes Section is prosecuting it .

The consequences for Wang at the indictment stage are the federal charge itself and his place in a takedown announcement that federal officials explicitly designed as a deterrent display; no arrest details, court appearance, or defense statement specific to Wang appeared in the fetched coverage .

Current Status

As of the October 22, 2026 announcement, Wang had been charged by indictment for the prohibited sale of prescription drug samples, with the FBI and HHS-OIG investigating and the case assigned to Assistant U.S. Attorney Sebastian Bellm. The coverage did not report his initial court appearance, a plea, or retention of counsel, and the prohibited-sale charge’s penalty exposure was not detailed in the announcement. His case proceeds alongside the other 14 takedown defendants .

Impact on Their Career/Life

A physician’s license exists to gatekeep exactly the act alleged here — controlling who may obtain prescription drugs and in what channel — and a federal indictment for selling samples to pharmacies that repackaged them for customers alleges the gatekeeping itself was sold off. The GLP-1 drugs named in the indictment, Rybelsus and Ozempic among them, have been among the most sought-after and supply-constrained medications in the country, a shortage context that makes sample diversion both more profitable and more visible to federal data systems. Wang now carries the only drug-diversion indictment in a takedown built to showcase $2 billion in health care fraud, with his name permanently attached to the Justice Department’s largest California announcement of the year .

Sources

• U.S. Attorney’s Office, Central District of California, “L.A. Health Care Fraud Takedown Results in 15 Defendants Charged, Including Six Medical Professionals, with $2 Billion in Losses Alleged,” October 22, 2026 — source
• The Mercury News / Silicon Valley, “DOJ charges 15 for $2 billion in fraudulent health care claims in California,” October 23, 2026 — source